X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-04 | LONA | Litton Mark James | Pres, CEO | S - Sale+OE | $5.37 | -5,156 | 59,894 | -8% | -$27,688 | |||||
| D | 2026-03-04 | LONA | Renninger Robert | CFO | S - Sale+OE | $5.37 | -906 | 15,851 | -5% | -$4,865 | |||||
| D | 2026-03-04 | LONA | Worthington Mark | GC, CCO | S - Sale+OE | $5.37 | -1,328 | 18,376 | -7% | -$7,131 | |||||
| D | 2026-03-04 | LONA | Church Kevin | CHIEF SCIENTIFIC OFFICER | S - Sale+OE | $5.37 | -1,359 | 25,178 | -5% | -$7,298 | |||||
| D | 2026-03-04 | LONA | San Martin Javier | CHIEF MEDICAL OFFICER | S - Sale+OE | $5.37 | -1,720 | 15,887 | -10% | -$9,236 | |||||
| D | 2026-01-02 | ATHA | San Martin Javier | CHIEF MEDICAL OFFICER | S - Sale+OE | $6.88 | -1,644 | 10,189 | -14% | -$11,311 | |||||
| D | 2026-01-02 | ATHA | Litton Mark James | Pres, CEO | S - Sale+OE | $6.88 | -2,586 | 42,796 | -6% | -$17,792 | |||||
| D | 2026-01-02 | ATHA | Renninger Robert | CFO | S - Sale+OE | $6.88 | -297 | 12,857 | -2% | -$2,043 | |||||
| D | 2026-01-02 | ATHA | Church Kevin | Chief Scientific Officer | S - Sale+OE | $6.88 | -876 | 20,681 | -4% | -$6,027 | |||||
| D | 2026-01-02 | ATHA | Worthington Mark | GC, CCO | S - Sale+OE | $6.88 | -876 | 13,978 | -6% | -$6,027 | |||||
| D | 2025-07-01 | ATHA | Church Kevin | Chief Scientific Officer | S - Sale+OE | $0.29 | -8,526 | 168,901 | -5% | -$2,502 | |||||
| D | 2025-07-01 | ATHA | Litton Mark James | Pres, CEO | S - Sale+OE | $0.29 | -25,123 | 345,491 | -7% | -$7,374 | |||||
| D | 2025-07-01 | ATHA | San Martin Javier | CHIEF MEDICAL OFFICER | S - Sale+OE | $0.29 | -10,842 | 71,665 | -13% | -$3,182 | |||||
| D | 2025-07-01 | ATHA | Worthington Mark | GC, CCO | S - Sale+OE | $0.29 | -8,526 | 111,875 | -7% | -$2,502 | |||||
| D | 2025-07-01 | ATHA | Renninger Robert | SVP, Finance, Accounting | S - Sale+OE | $0.29 | -2,897 | 109,186 | -3% | -$850 | |||||
| D | 2025-01-02 | ATHA | San Martin Javier | CHIEF MEDICAL OFFICER | S - Sale+OE | $0.56 | -10,826 | 35,841 | -23% | -$6,083 | |||||
| D | 2025-01-02 | ATHA | Litton Mark James | Pres, CEO | S - Sale+OE | $0.56 | -25,107 | 262,280 | -9% | -$14,108 | |||||
| D | 2025-01-02 | ATHA | Church Kevin | Chief Scientific Officer | S - Sale+OE | $0.56 | -8,510 | 130,761 | -6% | -$4,782 | |||||
| D | 2025-01-02 | ATHA | Renninger Robert | VP of Finance | S - Sale+OE | $0.56 | -2,881 | 89,724 | -3% | -$1,619 | |||||
| D | 2025-01-02 | ATHA | Worthington Mark | GC, CCO | S - Sale+OE | $0.56 | -8,510 | 83,735 | -9% | -$4,782 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |